Dermira (NASDAQ:DERM) Earning Somewhat Favorable Press Coverage, Study Finds
Media headlines about Dermira (NASDAQ:DERM) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dermira earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.9326855350044 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Prescribed Reading: Merger as a band-aid for biotech troubles (biopharmadive.com)
- Dermira, Inc. (NASDAQ:DERM) Receives Average Rating of “Hold” from Brokerages (americanbankingnews.com)
- Tesla Set to Raise $1.5 Billion for Model 3 Production (overnewsmagazine.com)
- Tesla’s (NASDAQ:TSLA) Market Perform Rating Reiterated at Oppenheimer Holdings, Inc (eslforkids.net)
- CENTRAL TRUST Co Raises Position in Tesla Inc. (NASDAQ:TSLA) (wisdomsave.com)
Shares of Dermira (NASDAQ:DERM) opened at 23.25 on Friday. The company has a 50-day moving average of $28.06 and a 200 day moving average of $30.67. The firm’s market capitalization is $966.99 million. Dermira has a 52 week low of $21.35 and a 52 week high of $38.75.
Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.89) by $0.04. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. The firm had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1 million. Equities research analysts anticipate that Dermira will post ($4.17) earnings per share for the current year.
A number of equities analysts have issued reports on the company. Evercore ISI assumed coverage on Dermira in a report on Thursday, June 29th. They set an “outperform” rating and a $48.00 target price for the company. BidaskClub upgraded Dermira from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Cantor Fitzgerald assumed coverage on Dermira in a report on Thursday, June 22nd. They set an “overweight” rating and a $45.00 target price for the company. Mizuho lowered their target price on Dermira from $42.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, May 25th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $46.00 target price on shares of Dermira in a report on Tuesday, July 18th. Five investment analysts have rated the stock with a sell rating and six have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $43.80.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/dermira-nasdaqderm-earning-somewhat-favorable-press-coverage-study-finds/1481093.html.
In other Dermira news, SVP Christopher M. Griffith sold 1,312 shares of the business’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $27.07, for a total value of $35,515.84. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Eugene A. Bauer sold 2,500 shares of the business’s stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $30.01, for a total transaction of $75,025.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,812 shares of company stock worth $482,231. Corporate insiders own 13.30% of the company’s stock.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.